PCM
ENVB icon

Penserra Capital Management’s Enveric Biosciences ENVB Stock Holding History

Penserra Capital Management’s Portfolio ENVB Stock Details ENVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-3
Closed -$52K – 1469
2021
Q2 		$52K Buy
+3
New +$64.3K ﹤0.01% 989

Other funds holding ENVB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SC
Scotia Capital Toronto, Ontario, Canada $26.8B AUM 33.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
IWC
Integrated Wealth Concepts Waltham, Massachusetts $20.5B AUM 24.45% 1-Year Est. Return

Penserra Capital Management's ENVB Position: Q3 2021 in Review

Penserra Capital Management sold out of Enveric Biosciences (ENVB) in Q3 2021, closing a stake of 3 shares — an estimated $52K sold.

Penserra Capital Management first reported a position in ENVB in Q2 2021 and held it in 1 quarter. The position peaked at $52K in Q2 2021. 18 funds tracked by Wall St. Rank hold ENVB as of Q3 2021.

  • Penserra Capital Management reported no remaining Enveric Biosciences position as of Q3 2021 after selling out during the quarter.
  • Penserra Capital Management sold 3 Enveric Biosciences shares in Q3 2021, an estimated $52K.
  • Penserra Capital Management first reported a position in Enveric Biosciences in Q2 2021 and held it in 1 quarter.
  • Penserra Capital Management's Enveric Biosciences position peaked at $52K in Q2 2021.
  • 18 funds tracked by Wall St. Rank held Enveric Biosciences as of Q3 2021.

Based on Penserra Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.